Adage Capital Partners Gp, L.L.C. Amylyx Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 8,800,000 shares of AMLX stock, worth $72.2 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
8,800,000
Previous 5,697,605
54.45%
Holding current value
$72.2 Million
Previous $20.2 Million
179.68%
% of portfolio
0.1%
Previous 0.04%
Shares
9 transactions
Others Institutions Holding AMLX
# of Institutions
144Shares Held
76MCall Options Held
212KPut Options Held
40.6K-
Perceptive Advisors LLC New York, NY7.9MShares$64.9 Million2.22% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$48.8 Million7.77% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.54MShares$37.2 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$36.9 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX3.26MShares$26.8 Million8.47% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $481M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...